Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease

Purpose of review APOE4 genotype is the strongest genetic risk factor for Alzheimer's disease. Prevailing evidence suggests that amyloid &bgr; plays a critical role in Alzheimer's disease. The objective of this article is to review the recent findings about the metabolism of apolipoprotein E (ApoE) and amyloid &bgr; and other possible mechanisms by which ApoE contributes to the pathogenesis of Alzheimer's disease. Recent findings ApoE isoforms have differential effects on amyloid &bgr; metabolism. Recent studies demonstrated that ApoE-interacting proteins, such as ATP-binding cassette A1 (ABCA1) and LDL receptor, may be promising therapeutic targets for Alzheimer's disease treatment. Activation of liver X receptor and retinoid X receptor pathway induces ABCA1 and other genes, leading to amyloid &bgr; clearance. Inhibition of the negative regulators of ABCA1, such as microRNA-33, also induces ABCA1 and decreases the levels of ApoE and amyloid &bgr;. In addition, genetic inactivation of an E3 ubiquitin ligase, myosin regulatory light chain interacting protein, increases LDL receptor levels and inhibits amyloid accumulation. Although amyloid &;-dependent pathways have been extensively investigated, there have been several recent studies linking ApoE with vascular function, neuroinflammation, metabolism, synaptic plasticity, and transcriptional regulation. For example, ApoE was identified as a ligand for a microglial receptor, TREM2, and studies suggested that ApoE may affect the TREM2-mediated microglial phagocytosis. Summary Emerging data suggest that ApoE affects several amyloid &bgr;-independent pathways. These underexplored pathways may provide new insights into Alzheimer's disease pathogenesis. However, it will be important to determine to what extent each mechanism contributes to the pathogenesis of Alzheimer's disease.

[1]  J. Schug,et al.  RXR controlled regulatory networks identified in mouse brain counteract deleterious effects of Aβ oligomers , 2016, Scientific Reports.

[2]  S. Leurgans,et al.  APOE and cerebral amyloid angiopathy in community-dwelling older persons , 2015, Neurobiology of Aging.

[3]  D. Holtzman,et al.  TREM2 Function in Alzheimer's Disease and Neurodegeneration. , 2016, ACS chemical neuroscience.

[4]  David M Holtzman,et al.  Human Apoe Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance Nih Public Access , 2022 .

[5]  N. Fitz,et al.  ATP-Binding Cassette Transporter A 1 : from metabolism to neurodegeneration , 2015 .

[6]  G. Rebeck,et al.  Apolipoprotein E Genotype Affects Size of ApoE Complexes in Cerebrospinal Fluid , 2016, Journal of Neuropathology and Experimental Neurology.

[7]  B. Nordestgaard,et al.  Loss-of-function mutation in ABCA1 and risk of Alzheimer's disease and cerebrovascular disease , 2015, Alzheimer's & Dementia.

[8]  D. Bredesen,et al.  Direct Transcriptional Effects of Apolipoprotein E , 2016, The Journal of Neuroscience.

[9]  Nick C Fox,et al.  Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis , 2012, The Lancet Neurology.

[10]  D. Holtzman,et al.  Human Apolipoprotein E4 Alters the Amyloid-β 40:42 Ratio and Promotes the Formation of Cerebral Amyloid Angiopathy in an Amyloid Precursor Protein Transgenic Model , 2005, The Journal of Neuroscience.

[11]  T. Montine,et al.  Different mechanisms of apolipoprotein E isoform‐dependent modulation of prostaglandin E2 production and triggering receptor expressed on myeloid cells 2 (TREM2) expression after innate immune activation of microglia , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[13]  M. Farzan,et al.  The Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E* , 2015, The Journal of Biological Chemistry.

[14]  P. Tontonoz,et al.  The E 3 ubiquitin ligase Idol controls brain LDL receptor expression , ApoE clearance , and A b amyloidosis , 2015 .

[15]  Nathan D. Price,et al.  IL-10 Alters Immunoproteostasis in APP Mice, Increasing Plaque Burden and Worsening Cognitive Behavior , 2015, Neuron.

[16]  G. Rebeck,et al.  Extracellular Proteolysis of Apolipoprotein E (apoE) by Secreted Serine Neuronal Protease , 2014, PloS one.

[17]  Guojun Bu,et al.  The role of APOE in cerebrovascular dysfunction , 2016, Acta Neuropathologica.

[18]  N. Fitz,et al.  ATP-binding cassette transporter A1: From metabolism to neurodegeneration , 2014, Neurobiology of Disease.

[19]  H. Chui,et al.  ABCA 1-Mediated Cholesterol Ef fl ux Capacity to Cerebrospinal Fluid Is Reduced in Patients With Mild Cognitive Impairment and Alzheimer ’ s Disease , 2016 .

[20]  I. Mook‐Jung,et al.  Amyloid β-interacting partners in Alzheimer's disease: From accomplices to possible therapeutic targets , 2016, Progress in Neurobiology.

[21]  D. Holtzman,et al.  microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain , 2015, The Journal of Neuroscience.

[22]  Jaekwang Kim,et al.  Apolipoprotein E in Synaptic Plasticity and Alzheimer’s Disease: Potential Cellular and Molecular Mechanisms , 2014, Molecules and cells.

[23]  M. Brug,et al.  Lack of Widespread BBB Disruption in Alzheimer’s Disease Models: Focus on Therapeutic Antibodies , 2015, Neuron.

[24]  D. Holtzman,et al.  Low-density Lipoprotein Receptor Represents an Apolipoprotein E-independent Pathway of Aβ Uptake and Degradation by Astrocytes* , 2012, The Journal of Biological Chemistry.

[25]  Mattias P. Karlsson,et al.  Apolipoprotein E4 Causes Age-Dependent Disruption of Slow Gamma Oscillations during Hippocampal Sharp-Wave Ripples , 2016, Neuron.

[26]  J. Gustafsson,et al.  Liver X receptors regulate cerebrospinal fluid production , 2016, Molecular Psychiatry.

[27]  D. Holtzman,et al.  The Role of Apolipoprotein E in Alzheimer's Disease , 2009, Neuron.

[28]  Lino C. Gonzalez,et al.  TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia , 2016, Neuron.

[29]  J. Attems,et al.  Capillary cerebral amyloid angiopathy identifies a distinct APOE ε4-associated subtype of sporadic Alzheimer’s disease , 2010, Acta Neuropathologica.

[30]  D. Holtzman,et al.  Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models , 2015, Acta neuropathologica communications.

[31]  C. Holmes,et al.  Aβ immunotherapy for Alzheimer’s disease: effects on apoE and cerebral vasculopathy , 2014, Acta Neuropathologica.

[32]  Michele Vendruscolo,et al.  An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Aβ42 aggregates linked with Alzheimer’s disease , 2016, Science Advances.

[33]  D. Holtzman,et al.  Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimer’s disease pathogenesis , 2015, Proceedings of the National Academy of Sciences.

[34]  J. Diedrich,et al.  HtrA1 Proteolysis of ApoE In Vitro Is Allele Selective. , 2016, Journal of the American Chemical Society.

[35]  S. Younkin,et al.  Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2)* , 2015, The Journal of Biological Chemistry.

[36]  G. W. Wong,et al.  Neurometabolic roles of ApoE and Ldl-R in mouse brain , 2016, Journal of Bioenergetics and Biomembranes.

[37]  M. Weiner,et al.  CSF Apo-E levels associate with cognitive decline and MRI changes , 2014, Acta Neuropathologica.

[38]  K. Rhodes,et al.  The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.

[39]  Thomas Wisniewski,et al.  Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid , 1992, Neuroscience Letters.

[40]  D. Holtzman,et al.  TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques , 2016, The Journal of experimental medicine.

[41]  J. Grutzendler,et al.  TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy , 2016, Neuron.

[42]  M. Laker.  Nutrition and metabolism. , 2004, Current opinion in lipidology.

[43]  G. Cole,et al.  Differential interaction of Apolipoprotein-E isoforms with insulin receptors modulates brain insulin signaling in mutant human amyloid precursor protein transgenic mice , 2015, Scientific Reports.

[44]  H. Chui,et al.  ABCA1‐Mediated Cholesterol Efflux Capacity to Cerebrospinal Fluid Is Reduced in Patients With Mild Cognitive Impairment and Alzheimer's Disease , 2016, Journal of the American Heart Association.

[45]  R. Mahley,et al.  Apolipoprotein E: Structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases , 2014, Neurobiology of Disease.

[46]  D. Holtzman,et al.  In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS , 2012, PloS one.

[47]  T. Saibara,et al.  Monocytic elastase-mediated apolipoprotein-E degradation: Potential involvement of microglial elastase-like proteases in apolipoprotein-E proteolysis in brains with Alzheimers disease. , 2015, Biochimica et biophysica acta.

[48]  S. Sajikumar,et al.  ApoE4 expression accelerates hippocampus-dependent cognitive deficits by enhancing Aβ impairment of insulin signaling in an Alzheimer’s disease mouse model , 2016, Scientific Reports.

[49]  D. Alkon,et al.  ApoE4 and Aβ Oligomers Reduce BDNF Expression via HDAC Nuclear Translocation , 2015, The Journal of Neuroscience.

[50]  Bradley T. Hyman,et al.  Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes , 2016, Proceedings of the National Academy of Sciences.

[51]  E. Diamandis,et al.  Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer’s disease patients and controls , 2014, Acta Neuropathologica.

[52]  F. LaFerla,et al.  Genetically Altering Aβ Distribution from the Brain to the Vasculature Ameliorates Tau Pathology , 2009, Brain pathology.

[53]  W. Banks,et al.  Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's disease , 2016, Experimental biology and medicine.

[54]  Hyejin Yoon,et al.  MicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease. , 2016, Biochimica et biophysica acta.